Cemiplimab 350mg/7ml solution for infusion vials
NHS hospitals in England used £43,068,712 of indicative cost of Cemiplimab 350mg/7ml solution for infusion vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 14.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Cemiplimab 350mg/7ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Cemiplimab 350mg/7ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Clatterbridge Cancer Centre Nhs Ft | £4,729,050 |
| Oxford University Hospitals Nhs Ft | £2,185,500 |
| Western Sussex Hospitals Nhs Found Trust | £2,111,100 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,966,950 |
| Royal Cornwall Hospitals Nhs Trust | £1,790,250 |
| Portsmouth Hospitals Nhs Trust | £1,753,050 |
| Royal Surrey County Hosp Nhs Found Trust | £1,469,400 |
| The Royal Marsden Nhs Foundation Trust | £1,339,200 |
| East And North Hertfordshire Nhs Trust | £1,329,900 |
| United Lincolnshire Hospitals Nhs Trust | £1,278,750 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.